NASDAQ:IMMP Prima BioMed (IMMP) Stock Price, News & Analysis $1.69 -0.01 (-0.59%) Closing price 04:00 PM EasternExtended Trading$1.74 +0.05 (+3.02%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Prima BioMed Stock (NASDAQ:IMMP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Prima BioMed alerts:Sign Up Key Stats Today's Range$1.66▼$1.7450-Day Range$1.52▼$2.4952-Week Range$1.32▼$2.72Volume64,776 shsAverage Volume191,365 shsMarket Capitalization$246.81 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company Overview Prima BioMed is a clinical‐stage biotechnology company specializing in the development of immuno‐oncology therapies. Founded in 2001 and headquartered in Sydney, Australia, the company applies its proprietary LAG-3 platform to modulate the immune response against cancer. This approach leverages both agonist and antagonist strategies to enhance antigen presentation and stimulate T-cell activity, aiming to overcome the limitations of existing checkpoint inhibitors. The company’s lead asset, eftilagimod alpha (IMP321), is a first‐in‐class soluble LAG-3 fusion protein designed to activate antigen‐presenting cells. Eftilagimod alpha is currently being evaluated in combination with pembrolizumab in Phase II trials for patients with metastatic breast cancer, building on earlier studies in melanoma and non‐small cell lung cancer. Prima BioMed’s pipeline also includes next‐generation LAG-3 antagonists that are in preclinical and early clinical development for solid tumors. Prima BioMed has pursued a global clinical development strategy, conducting trials across key oncology centers in North America, Europe and Australia. The company maintains research partnerships with leading academic institutions and collaborates with clinical investigators to advance its immunotherapy candidates. Prima BioMed’s intellectual property portfolio includes multiple patents covering LAG-3 mechanisms, therapeutic compositions and manufacturing processes. The company’s leadership team combines biotech industry veterans with deep expertise in oncology drug development and regulatory affairs. Executive Chairman Paul Hopper co‐founded Prima BioMed and brings extensive experience in life‐science funding and strategy, while Chief Executive Officer Marc Voigt oversees clinical operations and corporate development. Together, they guide Prima BioMed’s efforts to bring novel immunotherapies to patients with unmet medical needs.AI Generated. May Contain Errors. Read More Prima BioMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreIMMP MarketRank™: Prima BioMed scored higher than 19% of companies evaluated by MarketBeat, and ranked 845th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPrima BioMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrima BioMed has received no research coverage in the past 90 days.Read more about Prima BioMed's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Prima BioMed are expected to decrease in the coming year, from ($0.40) to ($0.50) per share.Price to Book Value per Share RatioPrima BioMed has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Prima BioMed's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.96% of the float of Prima BioMed has been sold short.Short Interest Ratio / Days to CoverPrima BioMed has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous monthShort interest in Prima BioMed has recently increased by 1.21%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrima BioMed does not currently pay a dividend.Dividend GrowthPrima BioMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.96% of the float of Prima BioMed has been sold short.Short Interest Ratio / Days to CoverPrima BioMed has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous monthShort interest in Prima BioMed has recently increased by 1.21%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A Search Interest3 people have searched for IMMP on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Prima BioMed to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prima BioMed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.07% of the stock of Prima BioMed is held by insiders.Percentage Held by InstitutionsOnly 2.32% of the stock of Prima BioMed is held by institutions.Read more about Prima BioMed's insider trading history. Receive IMMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prima BioMed and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMP Stock News HeadlinesImmutep’s Efti Combination Therapy Shows Promising Results in Soft Tissue Sarcoma TrialMay 28, 2025 | tipranks.comImmutep Limited: Immutep's Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue SarcomaMay 27, 2025 | finanznachrichten.deTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 9 at 2:00 AM | Porter & Company (Ad)Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue SarcomaMay 27, 2025 | globenewswire.comImmutep’s Efti Combination Therapy Achieves Success in Phase II Soft Tissue Sarcoma TrialMay 25, 2025 | tipranks.comImmutep reports promising lung cancer trial resultsMay 16, 2025 | investing.comImmutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung CancerMay 15, 2025 | finance.yahoo.comIs Immutep Limited (IMMP) the Best Australian Stock to Buy According to Analysts?May 15, 2025 | msn.comSee More Headlines IMMP Stock Analysis - Frequently Asked Questions How have IMMP shares performed this year? Prima BioMed's stock was trading at $2.17 at the start of the year. Since then, IMMP shares have decreased by 22.1% and is now trading at $1.69. How do I buy shares of Prima BioMed? Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prima BioMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prima BioMed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Pfizer (PFE), Broadcom (AVGO) and GE Aerospace (GE). Company Calendar Today7/09/2025Next Earnings (Estimated)7/29/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMMP CIK1506184 Webwww.immutep.com Phone(128) 315-7003Fax61-2-8569-1880Employees2,021Year FoundedN/APrice Target and Rating Average Price Target for Prima BioMed$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+305.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio18.86 Quick RatioN/A Sales & Book Value Annual Sales$5.14 million Price / Sales49.04 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book1.64Miscellaneous Outstanding Shares146,040,000Free Float141,556,000Market Cap$252.07 million OptionableOptionable Beta1.71 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:IMMP) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.